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Abstract 56 
The development of disinfectants with broad-range efficacy against bacteria, viruses, fungi, 57 
protozoa and prions constitutes an ongoing challenge. Prions, the causative agents of 58 
transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD) 59 
or its variant (vCJD) rank among the pathogens with the highest resistance to disinfection. 60 
Pilot studies have shown that procedures devised for prion disinfection were also highly 61 
effective against microbial pathogens. This fueled the idea to systematically exploit prions as 62 
test pathogens for the identification of new potential broad-range disinfectants. Prions 63 
essentially consist of misfolded, aggregated prion protein (PrP) and putatively replicate by 64 
nucleation-dependent, or seeded PrP polymerization. Recently, we have been able to 65 
establish PrP seeding activity as a quantitative in vitro indicator for the disinfection of 263K 66 
scrapie prions on steel wires used as surrogates for medical instruments. The seeding 67 
activity on wires re-processed in different disinfectants could be i) biochemically determined 68 
by quantitative protein misfolding cyclic amplification (qPMCA), ii) biologically detected after 69 
qPMCA in a cell assay, and iii) correctly translated into residual titres of scrapie infectivity. 70 
Our approach will substantially facilitate the identification of disinfectants with efficacy against 71 
prions as promising candidates for a further microbiological validation of broad-range activity.      72 
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Introduction 73 
The need for pathogen-free surgical instruments and medical devices   74 
Modern medicine depends on clean, pathogen-free materials and instruments. Therefore, 75 
safe disinfection is of utmost importance in the maintenance of re-usable surgical 76 
instruments and requires ongoing improvement in order to keep up with the challenge of 77 
newly emerging pathogens and increasingly complex medical devices. An ideal disinfectant 78 
would be effective against all classes of pathogens, suited for routine application, material-79 
friendly, compatible with heat-sensitive devices, and free of effects that fix proteins or other 80 
organic material. However, some microbial pathogens (e. g. bacterial spores, protozoal 81 
oocysts, mycobacteria, non-enveloped viruses or fungal spores) can be highly tolerant to 82 
disinfection.1 The same holds true for prions, the causative agents of transmissible 83 
spongiform encephalopathies such as ovine scrapie, bovine spongiform encephalopathy 84 
(BSE), or Creutzfeldt-Jakob disease and its variant in humans.  85 
Prions represent a biological principle of infection that substantially differs from that of 86 
bacteria, viruses, fungi or protozoa. Prions are essentially composed of a pathologically 87 
misfolded and aggregated isoform of the host-encoded prion protein referred to as PrPSc 2,3 or 88 
PrPTSE.4 The replication of prions is thought to occur via a mechanism of nucleation-89 
dependant, or seeded PrP polymerization.5,6 In this process PrPTSE oligomers or -polymers 90 
act as templates that recruit cellular prion protein (PrPC) and integrate it into their aggregate 91 
structure. When PrPTSE particles break up into smaller units PrP nuclei with proteinaceous 92 
seeding activity are multiplied which causes further autocatalytic replication of the 93 
pathological protein state. Being devoid of coding nucleic acids and characterized by an 94 
amyloid-like molecular structure prions rank amongst the most resistent pathogens in 95 
hierarchical scales of resistance to disinfection.1 96 
Epidemiological evidence suggests that transmission of human TSEs through contaminated 97 
medical instruments or devices can occur in invasive diagnostic or surgical procedures, and 98 
that such risk, while so far being only “hypothetical” for vCJD, is “real”  99 
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(i. e. effectively relevant) with respect to sporadic CJD (sCJD).7-14 Hence, safe re-processing 100 
of medical instruments and devices is mandatory not only for the prevention of nosocomial 101 
infections caused by microbial pathogens but also for the prevention of secondary 102 
transmissions of human prion diseases in hospitals and other medical settings. 103 
  104 
Towards integrated research on prion and microbial disinfection 105 
The development of disinfectants with simultaneous efficacy against bacteria and fungi 106 
(including spores), viruses, protozoa and prions constitutes a challenging task. This task has 107 
been additionally complicated by the fact that experimental research on classical microbial 108 
and prion disinfection was not tightly integrated for many years. So far, there is only a 109 
relatively small number of studies that have attempted to bridge this gap. In two reports, 110 
published in 200915 and 2010,16 different formulations that had been originally established for 111 
prion disinfection were shown, partly after targeted optimization, to be highly effective against 112 
bacteria, viruses and fungi as well. These findings demonstrated that in principle the 113 
disinfection of microbial pathogens and prions can be smoothly combined. They also 114 
provided a proof-of-concept that prions are not only a challenge but potentially also an 115 
informative paradigm for the broad-range disinfection of surgical instruments and medical 116 
devices. This fueled the idea to systematically exploit prions in future studies as model 117 
pathogens for the development of novel broad-range disinfectants. It has to be noted, 118 
however, that efficacy against prions does not necessarily imply that a disinfectant is also 119 
effective against other pathogens.1 Therefore, any claim for broad-range efficacy of 120 
formulations or processes with prioncidal activity needs to be carefully validated in 121 
appropriate microbiological test systems.     122 
Bioassays in animals provide the gold standard for the detection of prions and their 123 
inactivation.17,18 However, since they are time consuming, expensive, tightly restricted in 124 
throughput and potentially critical in both ethical and regulatory respect they do not provide a 125 
real option for the extensive screening of large numbers of disinfection samples. Biochemical 126 
testing for the removal, destablization or degradation of pathological prion protein PrPTSE, the 127 
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molecular surrogate marker for prion infectivity,19 has been performed as an alternative in 128 
disinfection studies using steel wires as surrogates for medical instruments and devices,15,20-129 
24 but this detection method is less reliable and sensitive than animal bioassays. Only during 130 
the past few years the situation has profoundly changed. The infectivity of certain prion 131 
strains can now be titrated by quantitative cell-based assays in solution or on solid test 132 
surfaces,25-27 and PrPTSE-associated seeding activity converting normal protease-sensitive 133 
PrPC into pathological and usually Proteinase K-resistant prion protein (PrPres) has become 134 
amenable to in vitro monitoring by protein misfolding cyclic amplification (PMCA).28,29 Recent 135 
technical advancements of the PMCA technology, called quantitative PMCA (qPMCA)30 and 136 
real-time quaking induced conversion assay (RT-QuIC),31 showed that the measurement of 137 
prion titres and PrPTSE seeding activity, respectively, are biochemically feasible in vitro with 138 
high sensitivity and accuracy. 139 
Since 2006 PMCA has been increasingly used for probing prion disinfection in vitro, initially 140 
in a non-quantitative manner32 and by now also in quantitative approaches.33,34 Prion 141 
replication by nucleation-dependent PrP polymerization implicates the seeding activity of 142 
PrPTSE as a key biochemical counterpart of biological prion infectivity. Based on this concept 143 
we examined in the recent study by Pritzkow et al.33 whether prion disinfection could be 144 
assessed without animal bioassays by biochemical and biological in vitro monitoring of PrP 145 
seeding activity. For this purpose we pursued a three-stage approach: The residual seeding 146 
activities on prion-contaminated steel wires that had been exposed to different disinfectants 147 
were at first biochemically determined by quantitative PMCA and translated into estimates of 148 
scrapie infectivity, and afterwards biologically detected in a non-quantitative cell assay by 149 
inoculation of glial cultures with qPMCA products derived from the test wires. Finally, the 150 
scrapie titre estimates from the qPMCA assay and the findings from the cell assay were 151 
compared to and validated by actual infectivity data from animal bioassays. The design, 152 
results and implications of this study33 which aimed at establishing a sensitive and practical 153 
screening test for prion disinfection are reviewed in the following sections of this article. 154 
 155 
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Probing prion disinfection in vitro 156 
PMCA-based seeding activity assay 157 
As a prerequisite for our study we first established a protocol for serial PMCA29,35,36 that 158 
allowed the quantitative detection of the seeding activity of 263K scrapie-associated PrPTSE 159 
in solution and on steel wires. In accordance with findings independently reported by others37 160 
we observed that the presence of glass beads in reaction batches substantially increased the 161 
sensitivity and robustness of PMCA. We also noticed that comprehensive precautionary 162 
measures aiming at the prevention of cross-contamination were required to warrant PMCA 163 
specificity in our hands. These safeguards included sealing and stringent decontamination of 164 
reaction tubes, collection of PMCA samples by vial puncture, and addition of the chaotropic 165 
prion-inactivating reagent guanidine thiocyanate to the water bath above the ultrasonic 166 
transducer. 167 
Next, we applied our protocol for quantitative PMCA to steel wires in a carrier assay for prion 168 
disinfection. Residual seeding activities on test steel wires that had been contaminated with 169 
10-1-diluted 263K scrapie hamster brain homogenate (SBH) and subsequently exposed to 170 
different disinfectants were quantitatively determined by comparing the PrPres amplification 171 
seeded by test steel wires to the PrPres amplification seeded by reference steel wires after 172 
1, 2, 3 and 4 rounds of qPMCA. Thus, our seeding activity assay was based on an internal 173 
calibration. The reference wires were contaminated with 10-1-, 10-2-, 10-3-, 10-4-, 10-5-, 10-6-, 174 
10-7- or 10-8-diluted SBH and carried known amounts of scrapie infectivity which had been 175 
determined in a previous study by endpoint titration in hamsters.38 We then used these 176 
infectivity titres of the reference steel wires as conversion factors in order to translate the 177 
seeding activities detected on test steel wires into estimates of 263K scrapie infectivity.  178 
 179 
Cell-based seeding activity assay 180 
Prion bioassays in animals essentially rely on the transmission of a TSE infection that 181 
eventually becomes evident by the onset of TSE-typical symptoms, cerebral 182 
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neuropathological changes (e. g. vacuolation) and/or accumulation of misfolded prion protein 183 
in the central nervous system. Thus, as to the formation, deposition and accumulation of 184 
PrPTSE, animal bioassays for prions basically detect PrP seeding as a biologically 185 
transmissible principle. In our disinfection study biologically transmissible PrP seeding 186 
activity that remained present on test steel wires after exposure to different disinfectants was 187 
indirectly detected by a surrogate cell assay for 263K scrapie prions. We found that primary 188 
cultures of hamster glial cells displayed both an accumulation of PrPres and amplification of 189 
PrP seeding activity upon exposure to 263K scrapie brain tissue or to PMCA products that 190 
were derived from steel wires contaminated with this prion strain. On this basis we subjected 191 
re-processed test steel wires to qPMCA for the biochemical detection and quantification of 192 
their residual seeding activity, and subsequently inoculated glial cultures with aliquots from 193 
such qPMCA reactions. Our non-quantitative glial assay confirmed the biological 194 
transmissibility of all PrP seeding activities that had been amplified from incompletely 195 
decontaminated wires.  196 
 197 
In vivo validation of seeding activity testing for prion disinfection   198 
Our in vitro assessment of prion disinfection was verified by comparing the estimated 199 
infectivity levels on the steel wires and the findings from the cell assay to actual scrapie titres 200 
that had been determined previously16,38 or in our present study in hamster bioassays for 201 
identical, similarly disinfected test carriers. We tested 15 different formulations or procedures 202 
for prion disinfection. While the test limit of hamster bioassays for the reduction of scrapie 203 
titres on test steel wires was found to be about 5.5 log10 units (logs),
38 at least 7 logs of 204 
seeding activity reduction could be monitored by qPMCA testing of steel wires. We found that 205 
the residual levels and reduction factors of scrapie infectivity indicated by the detected 206 
seeding activities were always consistent with, and within the detection limit of titrations in 207 
animals virtually identical to the findings from hamster bioassays. Taken together, the 208 
seeding activity of PrPTSE on test steel wires for prion disinfection could be biochemically 209 
titrated by qPMCA, biologically demonstrated by inoculation of glial cultures with qPMCA 210 
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products, and correctly translated into titres of prion infectivity. 211 
 212 
 213 
Conclusion and outlook 214 
Using prions as test pathogens in search of novel broad-range disinfectants  215 
The validation by cell assay and titration of qPMCA-detected seeding activity were found to 216 
indirectly reproduce two key features of animal bioassays in our study, i.e. a qualitative 217 
biological detection and quantitative determination of scrapie agent. The findings provided a 218 
proof-of-principle that cell assay-coupled qPMCA can substantially reduce, or possibly even 219 
replace, animal bioassays in screening studies of prion disinfection. This opens an avenue 220 
for the more extensive use of prions as potentially highly informative test pathogens when 221 
searching for novel braod-range disinfectants suitable for the routine maintenance of surgical 222 
instruments and medical devices.  223 
The decontamination of surgical instruments and medical devices usually comprises 224 
cleaning, disinfection and sterilisation. While cleaning refers to the reduction or removal of 225 
the mass of contaminating material from an instrument, disinfection and sterilisation reduce 226 
the biological infectivity of any pathogens remaining on an instrument after cleaning. We 227 
suggest a simple test schedule for the rapid in vitro screening of the efficacy of candidate 228 
formulations against prion contaminations on instrument surrogates: Firstly, in order to 229 
specify the cleaning efficacy with respect to the prion protein, the reduction of the total load 230 
of PrP (i.e PrPC and PrPTSE) on test wires will be tested by SDS-PAGE and Western blotting 231 
as described previously.20 Then, cell assay-coupled qPMCA will be used for gauging 232 
disinfection by an indirect quantitative in vitro assessment and biological detection of the 233 
prion infectivity that remains present on test carriers after re-processing. When the 234 
cleaning/disinfection solutions in which test wires had been incubated for decontamination 235 
are included in these analyses this will further elucidate the relative contributions of cleaning 236 
and inactivation to the reduction of the load of prion contamination. Formulations found to be 237 
 11 
sufficiently effective against prions in the screening procedures for cleaning and disinfection 238 
will be subsequently subjected to microbiological in vitro assays that test the efficacy against 239 
bacteria, viruses, fungi,15,16 and ideally also against protozoa. It has to be pointed out that our 240 
in vitro method for the screening of prion disinfectants intrinsically cannot reproduce all 241 
features of prion bioassays in animals. Therefore, formulations which show efficacy against 242 
prions and microbial pathogens in the preceding in vitro tests need to be finally validated for 243 
the reduction of prion infectivity by bioassays in animals.  244 
Several different studies have shown that the susceptibility to individual disinfection methods 245 
may vary between different prion strains.39-42 In the light of these findings it has been 246 
recommended that any prion inactivation procedures should be validated by bioassay 247 
against the prion strain for which they are intended to be used.41 This would require 248 
comprehensive experiments in animals, but there are no animal models commonly available 249 
that would allow the sensitive titration of the agents of vCJD and the different forms of sCJD 250 
over a broad range of infectivity. In order to further promote the development of novel highly-251 
effective disinfectants it might therefore be helpful to adapt PMCA- and cell culture protocols 252 
to the propagation and detection of PrP seeding activities associated with sCJD or vCJD.  253 
Furthermore, a pragmatic approach may focus on the most relevant human TSEs such as 254 
sCJD/subtypes MM1 and VV243 or vCJD when validating candidate formulations for broad-255 
range disinfection for their efficacy against human prions. 256 
    257 
Transmissible protein misfolding in prion diseases and beyond 258 
The proteinaceous seeding activity of PrPTSE transmits protein misfolding to cellular PrP in a 259 
cell-free manner in PMCA. This seeding activity seems to be also the driving force underlying 260 
the transmission of PrP misfolding at different levels of biological host organisms,  261 
i. e. from molecule-to-molecule, between cells, and in tissues.44 Because of their ability to 262 
transmit disease-causing PrP misfolding even between individuals, prions are genuinely 263 
infectious agents. According to a wealth of data nucleation-dependent, or seeded 264 
polymerization governs the misfolding and aggregation of proteins also in other amyloidoses 265 
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such as Alzheimer´s Disease (AD), type 2 diabetes or amyloid A amyloidosis.44 Yet, apart 266 
from TSEs, amyloid diseases are generally not considered as being infectious.  267 
The infectiousness of a human disease can be experimentally assessed in animal species 268 
that are closely related to humans. When inocula from more than 100 cases of AD were 269 
tested at the National Institutes of Health (USA) in primates for their ability to transmit 270 
disease this produced negative results with animals surviving an average of about 9 years 271 
(range: 1-24 years) after inoculation.45 However, other researchers claimed to have found 272 
evidence for an induction of amyloid- - (A -)amyloidosis in primates by intracerebral injection 273 
of AD brain homogenate46,47 and concluded that “beta (A4)-amyloidosis is a transmissible 274 
process comparable to the transmissibility of spongiform encephalopathy”.46 In fact, inducible 275 
protein misfolding diseases such as amyloid A amyloidosis or apolipoprotein A II amyloidosis 276 
show remarkable similarities to transmissible prion diseases,48 and an increasing number of 277 
publications recently reported the “molecular transmissibility”49 or “inducibility” of amyloidosis 278 
by intracerebral inoculation of proteins such as A 50 into susceptible laboratory animals. 279 
Notably, also the induction of cerebral A -amyloidosis through A -contaminated steel wires 280 
or peripherally applied A -rich extracts could be demonstrated in transgenic mice that 281 
expressed a mutant form of the human amyloid precursor protein (APP).51,52 These findings 282 
have been interpreted by some experts as indications for an infectious transmissibility of 283 
Alzheimer disease (AD), but they may rather reflect an acceleration of disease in genetically-284 
altered predisposed hosts than a genuine infection.53 The caveats to AD “transmission” were 285 
expressed also at various prion conferences, for example by TSE expert Paul W. Brown who 286 
has repeatedly pointed to the uniformly negative results for AD transmission in the 287 
comprehensive National Institutes of Health primate study.45   288 
Most recently Morales et al.54 described the induction by intracerebral injection of AD brain 289 
extracts of A -pathology in transgenic mice expressing human wild-type APP. Since such 290 
mice do not naturally develop amyloid deposits during their lifespan the reported findings of 291 
this study seem to suggest that A -deposition in the mouse brains had been caused by a 292 
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prion-like transmission and propagation of protein misfolding. At the end of their report the 293 
authors concluded: “It remains to be studied whether at least a proportion of AD cases could 294 
be initiated through a transmissible prion-like mechanism under natural conditions in 295 
humans”. Such possibility is still not proven. However, if proteinaceous seeding activity 296 
actually emerged as a naturally transmissible principle of non-PrP amyloids this would have 297 
far-reaching fundamental and practical implications55 - not least in the field of disinfection. 298 
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